ReviewClujul medical (1957)2013
Endocrine disrupting effects of butylated hydroxyanisole (BHA - E320).
Review in Clujul medical (1957), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Hazard Assessment of Antioxidants as Contaminants of Concern.Environmental science & technology letters · 2026Article
- Multi-AOP: a lightweight multi-view deep learning framework for antioxidant peptide discovery.Bioresources and bioprocessing · 2026Article
- Butylated Hydroxyanisole (BHA) Disrupts Brain Signalling in Embryo-Larval Stage of Zebrafish Leading to Attention Deficit Hyperactivity Disorder (ADHD).Journal of xenobiotics · 2025Article
- Metabolite Profiling and Antioxidant Activities in Seagrass Biomass.Marine drugs · 2025Article
- In vitro evaluation of antioxidant potential of polysaccharides and oligosaccharides extracted from three different seaweeds.Journal of food science and technology · 2024Article
- Purification and identification of novel antioxidant peptides derived fromBiochemistry and biophysics reports · 2024Article
- Potential Carcinogens in Makeup Cosmetics.International journal of environmental research and public health · 2023Article
- Antioxidant and Antibacterial Activity of Four Tannins Isolated from Different Sources and Their Effect on the Shelf-Life Extension of Vacuum-Packed Minced Meat.Foods (Basel, Switzerland) · 2023Article
- Encapsulation of Essential Oils in Nanocarriers for Active Food Packaging.Foods (Basel, Switzerland) · 2022Review
- Characterization of Novel Selected Microalgae for Antioxidant Activity and Polyphenols, Amino Acids, and Carbohydrates.Marine drugs · 2021Article
- Synthesis of Biobased Phloretin Analogues: An Access to Antioxidant and Anti-Tyrosinase Compounds for Cosmetic Applications.Antioxidants (Basel, Switzerland) · 2021Article
- The new kids on the block: Emerging obesogens.Advances in pharmacology (San Diego, Calif.) · 2021Review
- Identification of In Vitro Metabolites of Synthetic Phenolic Antioxidants BHT, BHA, and TBHQ by LC-HRMS/MS.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Butylated hydroxyanisole (BHA) is extensively used as antioxidant in foods, food packaging, cosmetics and pharmaceuticals. In the past years, it raised concerns regarding its possible endocrine disrupting effect. The existing in vitro studies indicate that BHA presents a weak estrogenic effect and also anti-androgenic properties while an in vivo study found it to have antiestrogenic properties. There is no sufficient data available at the moment to draw a conclusion regarding the safety of BHA when referring to its endocrine disrupting effect. Since a fraction of the population might be exposed to doses superior to the acceptable daily intake (ADI), it is important to gather more in vitro and in vivo data concerning the potential effects that BHA might have alone, but also in mixtures with natural hormones or other endocrine disrupting compounds.
Indexed as
Identifiers
26527908PMC4462476What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.